Literature DB >> 31974206

Elevated TRPV4 Levels Contribute to Endothelial Damage and Scarring in Experimental Spinal Cord Injury.

Hemant Kumar1, Chang Su Lim2, Hyemin Choi1, Hari Prasad Joshi1, Kyoung-Tae Kim3,4, Yong Ho Kim5, Chul-Kyu Park5, Hwan Myung Kim2, In-Bo Han6.   

Abstract

Currently, the role of transient receptor potential vanilloid type 4 (TRPV4), a nonselective cation channel in the pathology of spinal cord injury (SCI), is not recognized. Herein, we report the expression and contribution of TRPV4 in the pathology of scarring and endothelial and secondary damage after SCI. TRPV4 expression increased during the inflammatory phase in female rats after SCI and was expressed primarily by cells at endothelial-microglial junctions. Two-photon microscopy of intracellular-free Ca2+ levels revealed a biphasic increase at similar time points after SCI. Expression of TRPV4 at the injury epicenter, but not intracellular-free Ca2+, progressively increases with the severity of the injury. Activation of TRPV4 with specific agonist altered the organization of endothelial cells, affected tight junctions in the hCMEC/D3 BBB cell line in vitro, and increases the scarring in rat spinal cord as well as induced endothelial damage. By contrast, suppression of TRPV4 with a specific antagonist or in female Trpv4 KO mouse attenuated inflammatory cytokines and chemokines, prevented the degradation of tight junction proteins, and preserve blood-spinal cord barrier integrity, thereby attenuate the scarring after SCI. Likewise, secondary damage was reduced, and behavioral outcomes were improved in Trpv4 KO mice after SCI. These results suggest that increased TRPV4 expression disrupts endothelial cell organization during the early inflammatory phase of SCI, resulting in tissue damage, vascular destabilization, blood-spinal cord barrier breakdown, and scarring. Thus, TRPV4 inhibition/knockdown represents a promising therapeutic strategy to stabilize/protect endothelial cells, attenuate nociception and secondary damage, and reduce scarring after SCI.SIGNIFICANCE STATEMENT TRPV4, a calcium-permeable nonselective cation channel, is widely expressed in both excitable and nonexcitable cells. Spinal cord injury (SCI) majorly caused by trauma/accidents is associated with changes in osmolarity, mechanical injury, and shear stress. After SCI, TRPV4 was increased and were found to be linked with the severity of injury at the epicenter at the time points that were reported to be critical for repair/treatment. Activation of TRPV4 was damaging to endothelial cells that form the blood-spinal cord barrier and thus contributes to scarring (glial and fibrotic). Importantly, inhibition/knockdown of TRPV4 prevented these effects. Thus, the manipulation of TRPV4 signaling might lead to new therapeutic strategies or combinatorial therapies to protect endothelial cells and enhance repair after SCI.
Copyright © 2020 the authors.

Entities:  

Keywords:  TRPV4; blood–spinal cord barrier; endothelial cell; scarring; spinal cord injury; two-photon microscopy

Year:  2020        PMID: 31974206      PMCID: PMC7046444          DOI: 10.1523/JNEUROSCI.2035-19.2020

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  14 in total

Review 1.  The Provenance, Providence, and Position of Endothelial Cells in Injured Spinal Cord Vascular Pathology.

Authors:  Manjeet Chopra; Ankita Bhagwani; Hemant Kumar
Journal:  Cell Mol Neurobiol       Date:  2022-08-09       Impact factor: 4.231

Review 2.  Angiogenesis in Spinal Cord Injury: Progress and Treatment.

Authors:  Konstantinos Tsivelekas; Dimitrios Stergios Evangelopoulos; Dimitrios Pallis; Ioannis S Benetos; Stamatios A Papadakis; John Vlamis; Spyros G Pneumaticos
Journal:  Cureus       Date:  2022-05-30

Review 3.  Unveiling Leukocyte Extracellular Traps in Inflammatory Responses of the Central Nervous System.

Authors:  Francesca Colciaghi; Massimo Costanza
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

4.  Commentary on "The Role of Alginate Hydrogels as a Potential Treatment Modality for Spinal Cord Injury: A Comprehensive Review of the Literature".

Authors:  Hemant Kumar
Journal:  Neurospine       Date:  2022-06-30

5.  Neutrophil Extracellular Traps Exacerbate Secondary Injury via Promoting Neuroinflammation and Blood-Spinal Cord Barrier Disruption in Spinal Cord Injury.

Authors:  Zhou Feng; Lingxia Min; Liang Liang; Beike Chen; Hui Chen; Yi Zhou; Weiwei Deng; Hongliang Liu; Jingming Hou
Journal:  Front Immunol       Date:  2021-08-11       Impact factor: 7.561

6.  Resolvin D3 Promotes Inflammatory Resolution, Neuroprotection, and Functional Recovery After Spinal Cord Injury.

Authors:  Juri Kim; Hari Prasad Joshi; Seung Hun Sheen; Kyoung-Tae Kim; Jae Won Kyung; Hyemin Choi; Ye Won Kim; Su Yeon Kwon; Eun Ji Roh; Un Yong Choi; Seil Sohn; Yong Ho Kim; Chul-Kyu Park; Hemant Kumar; In-Bo Han
Journal:  Mol Neurobiol       Date:  2020-09-22       Impact factor: 5.590

7.  TRPV4: A trigger of pathological RhoA activation in neurological disease.

Authors:  Anna M Bagnell; Charlotte J Sumner; Brett A McCray
Journal:  Bioessays       Date:  2022-03-17       Impact factor: 4.653

8.  Systemic Administration of Fibroblast Growth Factor 21 Improves the Recovery of Spinal Cord Injury (SCI) in Rats and Attenuates SCI-Induced Autophagy.

Authors:  Sipin Zhu; Yibo Ying; Lin Ye; Weiyang Ying; Jiahui Ye; Qiuji Wu; Min Chen; Hui Zhu; Xiaoyang Li; Haicheng Dou; Huazi Xu; Zhouguang Wang; Jiake Xu
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

9.  Bazedoxifene, a Selective Estrogen Receptor Modulator, Promotes Functional Recovery in a Spinal Cord Injury Rat Model.

Authors:  Yiyoung Kim; Eun Ji Roh; Hari Prasad Joshi; Hae Eun Shin; Hyemin Choi; Su Yeon Kwon; Seil Sohn; Inbo Han
Journal:  Int J Mol Sci       Date:  2021-10-12       Impact factor: 5.923

Review 10.  Neutrophil, Extracellular Matrix Components, and Their Interlinked Action in Promoting Secondary Pathogenesis After Spinal Cord Injury.

Authors:  Sonam Dolma; Hemant Kumar
Journal:  Mol Neurobiol       Date:  2021-06-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.